MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
Wenqing Qi(University of Arizona), Daruka Mahadevan(The University of Texas MD Anderson Cancer Center)
Cited by 56
Related Papers
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
|International Journal of Molecular Sciences|2023|89